<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="11eb1f78-044c-4110-8f9b-a6b733972876"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold"/>
   </title>
   <effectiveTime value="20180621"/>
   <setId root="09b16a2d-825a-4d08-b86e-076548926916"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="059295980" root="1.3.6.1.4.1.519.1"/>
            <name>Mylan Pharmaceuticals Inc.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="970de340-89c2-4308-af13-af421d0f562f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20180621"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0378-8212" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Erythromycin</name>
                        <formCode code="C42934" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GEL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>erythromycin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="63937KV33D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ERYTHROMYCIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="63937KV33D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ERYTHROMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9XZ8H6N6OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0378-8212-93" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20181019"/>
                                          <high value="20250930"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0378-8212-60" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20181019"/>
                                          <high value="20250930"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050617" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA authorized generic"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20181019"/>
                              <high value="20250930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_693f0044-11ab-4d90-b29e-e8272081e186">
               <id root="693f0044-11ab-4d90-b29e-e8272081e186"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Erythromycin topical gel USP, 2% contains erythromycin (3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*,Â 13S*,  14R*)-4-[(2,6-Dideoxy-3-<content styleCode="italics">C</content>-methyl-3-<content styleCode="italics">O</content>-methyl-Î±-L-<content styleCode="italics">ribo</content>-hexopyranosyl)oxy]-14-ethyl-7,  12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3, 4, 6,-trideoxy-3-(dimethylamino)-Î²-D-<content styleCode="italics">xylo</content>-Â hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione), for topical dermatological use. Erythromycin is aÂ macrolide antibiotic produced from a strain of <content styleCode="italics">SaccaropolysporaerythraeaÂ </content>(formerly <content styleCode="italics">StreptomycesÂ erythreus</content>). It is a base and readily forms salts with acids.</paragraph>
                  <paragraph>Chemically, erythromycin is C<sub>37</sub>H<sub>67</sub>NO<sub>13</sub>. It has the following structural formula:</paragraph>
                  <renderMultiMedia ID="id-309408833" referencedObject="ID_00a2aecd-e4df-4de8-ab54-6295a8b603ac"/>
                  <paragraph>Erythromycin has a molecular weight of 733.94. It is a white or slightly yellow, odorless or practicallyÂ odorless, bitter crystalline powder. Erythromycin is very soluble in very polar organic solvents such asÂ alcohols, acetone, chloroform, acetonitrile and ethyl acetate. It is moderately soluble in less polarÂ solvents such as ether, dichloroethylene and amyl acetate. It is slightly soluble in nonpolar solventsÂ such as hexane. It is very poorly soluble in water.</paragraph>
                  <paragraph>Each gram of erythromycin topical gel USP, 2% contains 20 mg of erythromycin, USP in a vehicleÂ consisting of dehydrated alcohol and hydroxypropyl cellulose.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
               <component>
                  <observationMedia ID="ID_00a2aecd-e4df-4de8-ab54-6295a8b603ac">
                     <text>Erythromycin Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cc3d9bd6-c82c-4f68-baff-149669fbd3c9">
               <id root="cc3d9bd6-c82c-4f68-baff-149669fbd3c9"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known;Â however, the effect appears to be due in part to the antibacterial activity of the drug.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_32e1c620-f1b9-4c8a-a6d0-e3e8166feb03">
               <id root="32e1c620-f1b9-4c8a-a6d0-e3e8166feb03"/>
               <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
               <title>MICROBIOLOGY</title>
               <text>
                  <paragraph>Erythromycin acts by inhibition of protein synthesis in susceptible organisms by reversibly binding toÂ 50S ribosomal subunits, thereby inhibiting translocation of aminoacyl transfer-RNA and inhibitingÂ polypeptide synthesis. Antagonism has been demonstrated <content styleCode="italics">in vitro </content>between erythromycin, lincomycin, chloramphenicol, and clindamycin.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_1933addc-4b6d-496f-bfaa-c78be623c6e6">
               <id root="1933addc-4b6d-496f-bfaa-c78be623c6e6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Erythromycin topical gel is indicated for the topical treatment of acne vulgaris.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_a720b1d8-d78d-44ba-a087-c55c44ce961c">
               <id root="a720b1d8-d78d-44ba-a087-c55c44ce961c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Erythromycin topical gel is contraindicated in those individuals who have shownÂ hypersensitivity to any of its components.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_bb772e63-bbf6-4103-aaf3-c32a4924339c">
               <id root="bb772e63-bbf6-4103-aaf3-c32a4924339c"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Pseudomembranous colitis has been reported with nearly all antibacterial agents, includingÂ erythromycin, and may range in severity from mild to life-threatening. Therefore, it is importantÂ to consider this diagnosis in patients who present with diarrhea subsequent to the administrationÂ of antibacterial agents.</content>
                  </paragraph>
                  <paragraph>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth ofÂ clostridia. Studies indicate that a toxin produced by <content styleCode="italics">Clostridium difficileÂ </content>is one primary cause ofÂ âantibiotic-associated colitisâ. After the diagnosis of pseudomembranous colitis has been established,Â therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond toÂ drug discontinuation alone. In moderate to severe cases, consideration should be given to managementÂ with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinicallyÂ effective against <content styleCode="italics">C. difficileÂ </content>colitis.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_520424ca-be4b-42a7-8f76-136c4468fe0a">
               <id root="520424ca-be4b-42a7-8f76-136c4468fe0a"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20180621"/>
               <component>
                  <section ID="ID_a7fba0e0-da3d-4984-8bc9-a4749296f524">
                     <id root="a7fba0e0-da3d-4984-8bc9-a4749296f524"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>For topical use only; not for ophthalmic use. Concomitant topical acne therapy should be used withÂ caution because a possible cumulative irritancy effect may occur, especially with the use of peeling,Â desquamating or abrasive agents.</paragraph>
                        <paragraph>Avoid contact with eyes and all mucous membranes.</paragraph>
                        <paragraph>The use of antibiotic agents may be associated with the overgrowth of antibiotic-resistant organisms. IfÂ this occurs, discontinue use and take appropriate measures.</paragraph>
                     </text>
                     <effectiveTime value="20180621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_600a49e9-5e4d-4ff6-93fd-50f0b7488a7a">
                     <id root="600a49e9-5e4d-4ff6-93fd-50f0b7488a7a"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients using Erythromycin topical gel should receive the following information andÂ instructions:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>This medication is to be used as directed by the physician. It is for external use only. AvoidÂ contact with the eyes, nose, mouth, and all mucous membranes.<br/>
                           </item>
                           <item>
                              <caption>2.</caption>This medication should not be used for any disorder other than that for which it was prescribed.<br/>
                           </item>
                           <item>
                              <caption>3.</caption>Patients should not use any other topical acne medication unless otherwise directed by theirÂ physician.<br/>
                           </item>
                           <item>
                              <caption>4.</caption>Patients should report to their physician any signs of local adverse reactions.</item>
                        </list>
                     </text>
                     <effectiveTime value="20180621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9dec4f89-481a-4605-8d23-f9105a262715">
                     <id root="9dec4f89-481a-4605-8d23-f9105a262715"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No animal studies have been performed to evaluate carcinogenic and mutagenic potential, or effects onÂ fertility of topical erythromycin. However, long-term (2-year) oral studies in rats with erythromycinÂ ethylsuccinate and erythromycin base did not provide evidence of tumorigenicity. There was noÂ apparent effect on male or female fertility in rats fed erythromycin (base) at levels up to 0.25% of diet.</paragraph>
                     </text>
                     <effectiveTime value="20180621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a6a2847a-ee60-431f-8ce5-b0a2b29fda8a">
                     <id root="a6a2847a-ee60-431f-8ce5-b0a2b29fda8a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>There was no evidence of teratogenicity or any other adverse effect on reproduction in female rats fedÂ erythromycin base (up to 0.25% of diet) prior to and during mating, during gestation and throughÂ weaning of two successive litters. There are, however, no adequate and well-controlled studies inÂ pregnant women. Because animal reproduction studies are not always predictive of human response, thisÂ drug should be used in pregnancy only if clearly needed. Erythromycin has been reported to cross theÂ placental barrier in humans, but fetal plasma levels are generally low.</paragraph>
                     </text>
                     <effectiveTime value="20180621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6dd9dfd7-1872-4185-8a30-c3c1c3430223">
                     <id root="6dd9dfd7-1872-4185-8a30-c3c1c3430223"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Women</title>
                     <text>
                        <paragraph>It is not known whether erythromycin is excreted in human milk after topical application. However,Â erythromycin is excreted in human milk following oral and parenteral erythromycin administration.Â Therefore, caution should be exercised when erythromycin is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20180621"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_580b905e-123c-4969-b2fa-bc799a5dcaf1">
                     <id root="580b905e-123c-4969-b2fa-bc799a5dcaf1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Keep this and all medication out of the reach of children.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20180621"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_fe946fc3-fc0b-4fb1-8a77-3fb5a13b5070">
               <id root="fe946fc3-fc0b-4fb1-8a77-3fb5a13b5070"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>In controlled clinical trials, the incidence of burning associated with erythromycin topical gel was approximately 25%. The following additional local adverse reactions have been reportedÂ occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness ofÂ the skin have also been reported with the topical use of erythromycin. A generalized urticarial reaction,Â possibly related to the use of erythromycin, which required systemic steroid therapy has been reported.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_e4da45fd-5e81-464f-aec2-b468b7a515e7">
               <id root="e4da45fd-5e81-464f-aec2-b468b7a515e7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Erythromycin topical gel should be applied sparingly as a thin film to affected area(s) once orÂ twice a day after the skin is thoroughly cleansed and patted dry. If there has been no improvement after 6Â to 8 weeks, or if the condition becomes worse, treatment should be discontinued, and the physicianÂ should be reconsulted. Spread the medication lightly rather than rubbing it in. There are no data directlyÂ comparing the safety and efficacy of b.i.d. versus q.d. dosing.</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_1ac353b5-d096-40f9-a688-9ccf6ae09f3a">
               <id root="1ac353b5-d096-40f9-a688-9ccf6ae09f3a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Erythromycin Topical Gel USP, 2% contains 20 mg of erythromycin, USP per gram. The clear to slightly yellow gel is available as follows:</paragraph>
                  <paragraph>NDC 0378-8212-93<br/>carton containing one 30 g tube</paragraph>
                  <paragraph>NDC 0378-8212-60<br/>carton containing one 60 g tube</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_9001f347-0a2a-4295-80af-fc1aaf64fc8f">
               <id root="9001f347-0a2a-4295-80af-fc1aaf64fc8f"/>
               <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
               <title>STORAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NOTE: FLAMMABLE. KEEP AWAY FROM HEAT AND FLAME.</content>
                  </paragraph>
                  <paragraph>Store and dispense in original container.Â Keep tube tightly closed.Â <content styleCode="bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F).  [See USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Pharmaceuticals Inc.<br/>
                     </content>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">DPT Laboratories, Ltd.<br/>
                     </content>San Antonio, TX 78215 U.S.A.</paragraph>
                  <paragraph>Revised: 6/2018<br/>DPT:ERYTOPG:R2</paragraph>
                  <paragraph>140976-0618</paragraph>
               </text>
               <effectiveTime value="20180621"/>
            </section>
         </component>
         <component>
            <section ID="ID_7afab87a-b906-453d-add3-19e5cac22a65">
               <id root="7afab87a-b906-453d-add3-19e5cac22a65"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL â 2%</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 0378-8212-93</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Erythromycin<br/>Topical Gel, USP<br/>2%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Dermatologic<br/>Use Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Not for Ophthalmic Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Description:</content> Erythromycin<br/>Topical Gel USP, 2% contains<br/>erythromycin, USP (20 mg/g)<br/>in a vehicle consisting of<br/>dehydrated alcohol and<br/>hydroxypropyl cellulose.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Usual Dosage:</content> Erythromycin<br/>Topical Gel USP, 2% should<br/>be applied sparingly as a thin<br/>film to affected area(s) once<br/>or twice a day after the skin<br/>is thoroughly cleansed and<br/>patted dry. Spread the<br/>medication lightly rather than<br/>rubbing it in. The hands<br/>should be washed after<br/>application. See<br/>accompanying prescribing<br/>information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep this and all<br/>medication out of the<br/>reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOTE: FLAMMABLE. KEEP<br/>AWAY FROM HEAT AND<br/>FLAME.</content>
                  </paragraph>
                  <paragraph>Keep tube tightly closed.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20Â° to 25Â°C (68Â° to<br/>77Â°F). [See USP Controlled<br/>Room Temperature.]</content>
                  </paragraph>
                  <paragraph>To open, reverse cap and push<br/>pointed top into neck seal.<br/>To close, screw cap onto tube.</paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Pharmaceuticals Inc.<br/>
                     </content>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">DPT Laboratories, Ltd.<br/>
                     </content>San Antonio, TX 78215 U.S.A.</paragraph>
                  <paragraph>DPT:8212:93:1C:R2 117509-0618</paragraph>
                  <paragraph>
                     <content styleCode="bold">Mylan.com</content>
                  </paragraph>
                  <renderMultiMedia ID="id1282602781" referencedObject="ID_9cfa45a9-1a01-448b-a6f3-24c8064fc5ca"/>
               </text>
               <effectiveTime value="20180621"/>
               <component>
                  <observationMedia ID="ID_9cfa45a9-1a01-448b-a6f3-24c8064fc5ca">
                     <text>Erythromycin Topical Gel 2% Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>